CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, to detect Transthyretin cardiac amyloidosis (ATTR-CA). Thus, this study will assess Willem™ ability to distinguish between truly diagnosed ATTR-CA patients and confirmed non-ATTR-CA patients from ECG data.
Subjects ≥ 18 years old
Subjects with 12-leads ECG records with a 10 seconds minimum length on digital format
Patients with paced rhythm on the ECG.
Idoven 1903 S.L.
Lead sponsor
AstraZeneca
Collaborator